Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile

Wolfgang Haas1, Lynne S Gearinger1, Dale W Usner2, Heleen H DeCory3, Timothy W Morris11Microbiology and Sterilization Sciences, 2Clinical Affairs, 3Global Pharmaceutical Medical Affairs, Bausch and Lomb Inc, Rochester, NY, USABackground: The purpose of this paper is to report on the bacterial specie...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2011
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/e2fec0c97a17436a9bacb9f0005301ca
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:e2fec0c97a17436a9bacb9f0005301ca
record_format	dspace
spelling	oai:doaj.org-article:e2fec0c97a17436a9bacb9f0005301ca2021-12-02T06:19:04ZIntegrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile1177-54671177-5483https://doaj.org/article/e2fec0c97a17436a9bacb9f0005301ca2011-09-01T00:00:00Zhttp://www.dovepress.com/integrated-analysis-of-three-bacterial-conjunctivitis-trials-of--a8328https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Wolfgang Haas1, Lynne S Gearinger1, Dale W Usner2, Heleen H DeCory3, Timothy W Morris11Microbiology and Sterilization Sciences, 2Clinical Affairs, 3Global Pharmaceutical Medical Affairs, Bausch and Lomb Inc, Rochester, NY, USABackground: The purpose of this paper is to report on the bacterial species isolated from patients with bacterial conjunctivitis participating in three clinical trials of besifloxacin ophthalmic suspension, 0.6%, and their in vitro antibacterial susceptibility profiles.Methods: Microbial data from three clinical studies, conducted at multiple clinical sites in the US and Asia were integrated. Species were identified at a central laboratory, and minimum inhibitory concentrations were determined for various antibiotics, including &beta;-lactams, fluoroquinolones, and macrolides.Results: A total of 1324 bacterial pathogens representing more than 70 species were isolated. The most common species were Haemophilus influenzae (26.0%), Streptococcus pneumoniae (22.8%), Staphylococcus aureus (14.4%), and Staphylococcus epidermidis (8.4%). H. influenzae was most frequently isolated among patients aged 1&ndash;18 years, while S. aureus was most prevalent among those &gt;65 years. Drug resistance was prevalent: Of H. influenzae isolates, 25.3% were &beta;-lactamase positive and 27.2% of S. pneumoniae isolates were penicillin-intermediate/resistant; of S. aureus isolates, 13.7% were methicillin-resistant (MRSA), and of these, 65.4% were ciprofloxacin-resistant, while 45.9% of S. epidermidis isolates were methicillin-resistant (MRSE), and, of these, 47.1% were ciprofloxacin-resistant. Besifloxacin was more potent than comparator fluoroquinolones overall, and particularly against Gram-positive bacteria. Against ciprofloxacin-resistant MRSA and MRSE, besifloxacin was four-fold to &ge; 128-fold more potent than other fluoroquinolones.Conclusions: While the pathogen distribution in bacterial conjunctivitis has not changed, drug resistance is increasing. Patient age and local antibiotic resistance trends should be considered in the treatment of this ocular infection. Besifloxacin showed broad-spectrum in vitro activity and was particularly potent against multidrug-resistant staphylococcal isolates.Keywords: besifloxacin, fluoroquinolones, in vitro activity, ocular isolates, bacterial conjunctivitis&nbsp;Haas WGearinger LSUsner DWDeCory HHMorris TWDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 1369-1379 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Haas W Gearinger LS Usner DW DeCory HH Morris TW Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
description	Wolfgang Haas1, Lynne S Gearinger1, Dale W Usner2, Heleen H DeCory3, Timothy W Morris11Microbiology and Sterilization Sciences, 2Clinical Affairs, 3Global Pharmaceutical Medical Affairs, Bausch and Lomb Inc, Rochester, NY, USABackground: The purpose of this paper is to report on the bacterial species isolated from patients with bacterial conjunctivitis participating in three clinical trials of besifloxacin ophthalmic suspension, 0.6%, and their in vitro antibacterial susceptibility profiles.Methods: Microbial data from three clinical studies, conducted at multiple clinical sites in the US and Asia were integrated. Species were identified at a central laboratory, and minimum inhibitory concentrations were determined for various antibiotics, including &beta;-lactams, fluoroquinolones, and macrolides.Results: A total of 1324 bacterial pathogens representing more than 70 species were isolated. The most common species were Haemophilus influenzae (26.0%), Streptococcus pneumoniae (22.8%), Staphylococcus aureus (14.4%), and Staphylococcus epidermidis (8.4%). H. influenzae was most frequently isolated among patients aged 1&ndash;18 years, while S. aureus was most prevalent among those &gt;65 years. Drug resistance was prevalent: Of H. influenzae isolates, 25.3% were &beta;-lactamase positive and 27.2% of S. pneumoniae isolates were penicillin-intermediate/resistant; of S. aureus isolates, 13.7% were methicillin-resistant (MRSA), and of these, 65.4% were ciprofloxacin-resistant, while 45.9% of S. epidermidis isolates were methicillin-resistant (MRSE), and, of these, 47.1% were ciprofloxacin-resistant. Besifloxacin was more potent than comparator fluoroquinolones overall, and particularly against Gram-positive bacteria. Against ciprofloxacin-resistant MRSA and MRSE, besifloxacin was four-fold to &ge; 128-fold more potent than other fluoroquinolones.Conclusions: While the pathogen distribution in bacterial conjunctivitis has not changed, drug resistance is increasing. Patient age and local antibiotic resistance trends should be considered in the treatment of this ocular infection. Besifloxacin showed broad-spectrum in vitro activity and was particularly potent against multidrug-resistant staphylococcal isolates.Keywords: besifloxacin, fluoroquinolones, in vitro activity, ocular isolates, bacterial conjunctivitis&nbsp;
format	article
author	Haas W Gearinger LS Usner DW DeCory HH Morris TW
author_facet	Haas W Gearinger LS Usner DW DeCory HH Morris TW
author_sort	Haas W
title	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
title_short	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
title_full	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
title_fullStr	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
title_full_unstemmed	Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
title_sort	integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/e2fec0c97a17436a9bacb9f0005301ca
work_keys_str_mv	AT haasw integratedanalysisofthreebacterialconjunctivitistrialsofbesifloxacinophthalmicsuspension06etiologyofbacterialconjunctivitisandantibacterialsusceptibilityprofile AT gearingerls integratedanalysisofthreebacterialconjunctivitistrialsofbesifloxacinophthalmicsuspension06etiologyofbacterialconjunctivitisandantibacterialsusceptibilityprofile AT usnerdw integratedanalysisofthreebacterialconjunctivitistrialsofbesifloxacinophthalmicsuspension06etiologyofbacterialconjunctivitisandantibacterialsusceptibilityprofile AT decoryhh integratedanalysisofthreebacterialconjunctivitistrialsofbesifloxacinophthalmicsuspension06etiologyofbacterialconjunctivitisandantibacterialsusceptibilityprofile AT morristw integratedanalysisofthreebacterialconjunctivitistrialsofbesifloxacinophthalmicsuspension06etiologyofbacterialconjunctivitisandantibacterialsusceptibilityprofile
_version_	1718400023799005184

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile

Documents similaires